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Introduction
Active tumor immunotherapy by vaccination with irradiated neoplastic cells is expected to activate an immune response against the entire repertoire of tumorassociated antigens (TAA), a few of which have been molecularly defined. 1, 2 Data have emerged that encourage the use of cellular-based vaccines for melanoma patients. 3, 4 Active immunotherapy can be further improved by genetic modification of tumor cells through insertion and expression of cytokine genes. 5 In fact, preclinical studies have shown that the injection of such engineered tumor cells induces a local inflammatory reaction leading to the activation of a systemic antitumor memory response and, in some cases, to the cure of established tumors. 6 A major issue in the use of cell-based vaccines is the role of the different antigens or subsets of antigens expressed by tumor cells in eliciting a T cell response determining tumor regression. In fact, CTL responses against immunodominant antigens, such as melanomaassociated MART-1/MelanA or Pmel17/gp100, can mediate in vivo destruction of antigen-positive tumor cells but also select for antigen loss variants. It has been reported that during tumor progression, antigenic variants can appear which may loose not only the HLA class I molecules, but also T cell epitopes. [7] [8] [9] In this study we have analyzed the CD8 T cell response associated with the therapeutic activity following IL-12-transduced tumor cell vaccination. Considering that immunization may direct the immune response against an antigen that is therapeutically irrelevant or lost because of immune selection, we have set up a model system in which vaccination therapy is directed to a tumor carrying more than one known antigen. This enables testing which antigen is the relevant target of host-induced immune response but also the relationship between immunodominance and immunoselection. We used the C26 colon carcinoma which expresses as immunodominant TAA the L d restricted peptide gp70 (423-431), called AH1, encoded by env gene of the endogenous ecotropic murine leukemia virus (MuLV) emv-1. 10 In addition, C26 express at least one additional, but as yet molecularly undefined, subdominant tumor rejection antigen recognized by a CTL clone, 11 TA9A (tumor anti- IL-12 was chosen because of its potent antitumor effects. 14 We have previously reported that vaccination with irradiated C26 cells engineered to produce IL-12 were more active than C26 cells transduced with IL-2 in curing mice bearing C51, another colon carcinoma sharing the emv-1-derived TAA. 15 We have now examined whether the antigen specificity and cytokine profile of CTL generated by IL-12 vaccine can be associated with tumor eradication or with progression of antigen loss variants.
Results
Active immunotherapy with C26/IL-12/FR␣ tumor cell is dependent on CD8 + T lymphocytes C26 cells engineered to produce IL-12 and to express the human FR␣ (C26/IL-12/FR␣) were used to treat mice bearing lung metastases of C26/FR␣. Cell vaccination, given s.c. biweekly for 2 weeks, cured 13 of 26 mice while all 29 untreated counterparts died of lung metastases within 50 days (Figure 1a , P Ͻ 0.0001 by log-rank test). IL-12 production determined the efficacy of the vaccine, since treatment with C26/FR␣ cells (not transduced with IL-12 genes) did not change mice survival significantly (Figure 1b) . The therapeutic effect was dependent on host CD8 T cells. In fact, no cures or increase of survival time were observed in CD8-depleted, vaccinated mice ( Figure  1c ). In contrast, the effectiveness of C26/IL-12/FR␣ cell vaccination was not changed by depletion of CD4 lymphocytes: in fact five of 13 vaccinated mice were cured while 13 of 13 controls died of metastatic disease ( Figure  1d , P Ͻ 0.001).
We then tested whether partial splenectomy performed at the end of vaccination therapy affected the treatment outcome. Figure 1e shows survival curves of controls and vaccinated mice that underwent hemisplenectomy 3 days after the last vaccine injection (day 16). Partial spleen removal by surgery did not change the rate of survivors (five of 10 cured mice, P Ͻ 0.01) or the survival time from that of non-splectomized mice reported in Figure 1a . This surgical procedure enabled us to collect individual lymphocyte samples after vaccination and to analyze the antitumor response in mice identified as responders or nonresponders on the basis of the therapeutic outcome.
CTL from cured mice (responders) display a preferential recognition of C26-related TAA/s on C26/FR␣ cells than CTL from nonresponder mice Lymphocytes from mice vaccinated with C26/IL-12/FR␣ were tested for CTL activity against a panel of target cells expressing different TAAs of the C26/FR␣ tumor. Cytolysis was directed against C26 and syngeneic F1-transformed fibroblasts pulsed with the AH1 peptide, the immunodominant CTL antigen eluted from the C26 variant CT26, 10 but not against F1 cells not pulsed or pulsed with an irrelevant peptide (not shown). CTL were also Comparison of anti-C26 CTLp frequencies between responders and nonresponders by LDA further confirmed these data ( Figure 3a) . Frequencies of CTLp directed to C26 evaluated simultaneously in three different experiments ranged between 87 and 141 CTLp/10 7 lymphocytes for nonresponders and between 266 and 419 CTLp/10 7 lymphocytes for responder mice, while similar (Figure 4 , upper panel), a result consistent with the different CTL response to C26-related TAA described above.
Figure 3 Frequencies of anti-C26 (a) and anti-AH1 (b) CTLp in lymphocytes from responder and nonresponder mice, and frequencies of CTLp producing GM-CSF obtained in the same LDA (c
On the contrary, the levels of GM-CSF produced by CD8 lymphocytes from responder mice were significantly higher than those of lymphocytes from nonresponder mice regardless of the type of stimulating cells ( Figure 4 , lower panel). In addition, these data indicate that C26-related TAA other than AH1 were recognized by CD8 cells from responders.
The difference in GM-CSF release by antigen-specific CD8 cells between responders and nonresponders was further confirmed by LDA. Although the frequencies of anti-AH1 CTLp between responders and nonresponders was similar (Figure 3b ), the frequency of T cell precursors producing GM-CSF measured within the same assay was higher in responders than in nonresponders (Figure 3c ).
Tumor cells isolated from pulmonary metastases of nonresponder mice lack FR␣ but retain C26 TAA expression Since a strong antitumor CTL response was shown in nonresponder mice which did not benefit from vaccination therapy, we asked whether antigen loss tumor variants outgrew and killed these mice. Tumors obtained at death from vaccinated mice showed a complete lack (seven of nine tumors) or reduction below 50% positivity (two of nine tumors) of FR␣ expression as detected by flow cytometry with FR␣-specific mAb. The same analysis carried out on tumors obtained at death from nonvaccinated controls, showed that only two of nine tumors were negative for FR␣ expression (Figure 5a , P Ͻ 0.0001 by Student's t test).
The same type of analysis was performed at the end of vaccination in mice depleted of CD8 or CD4 cells. Mice were killed and lung tumors were tested for FR␣ expression. In CD8-depleted mice tumor progression occurred despite vaccination (see Figure 1c) and FR␣ on these tumors remained highly expressed (Figure 5b ), suggesting that in the absence of CD8 immunoselection did not take place. On the contrary, CD4 depletion, which did not reduce the efficacy of vaccination (see Figure 1d ) allowed selection of FR␣-negative variants; in fact FR␣ was detected in less than 50% of tumor cells (Figure 5c ). Since tumors from cured mice cannot be examined, the data suggest that immunoselection of FR␣ is likely to occur in all vaccinated mice.
To test whether the 'endogenous' set of TAA present on C26 underwent immunoselection, their expression was tested using the CTL clone TIL/26 recognizing AH1 peptide and the CTL clone 9A/89 specific for the as yet undefined, subdominant C26 antigen TAA9A. Six tumors removed at death from vaccinated mice, four showing loss and two showing reduction of FR␣ expression in the experiment reported in Figure 5a , were tested as stimulating cells for induction of IFN␥ release by anti-C26 and anti-FR␣ CTL clones. All tumors were recognized by CTL clones TIL/26 and 9A/89, indicating that C26 TAAs were expressed, whereas only two of six tumors were recognized by anti-FR␣ CTL clone IF1 (Figure 6 ), thus confirming immunostaining data. All CTL clones were shown to recognize C26/FR␣ but not F1 cells maintained in culture (not shown). These data indicate that FR␣ but not C26-related TAAs were immunoselected in vivo after vaccination.
We tested the possibility that antigen loss could also be due to in vivo outgrowth of FR␣ nontransduced cells. Four tumors lacking FR␣ expression were found to be G418 resistant when recultured in vitro, suggesting that the transduced genes were not lost but rather down-regulated. In fact, treatment of tumor cells with the demethylating agent aza restored FR␣ expression, albeit in a limited fraction of cells, in all tested tumors as detected by FACS analysis (Table 1) .
Discussion
Several clinical phase I studies have been initiated to test the effects of vaccinations with gene-modified tumor cells or peptides. 2, 5 The efficacy of vaccination on the generation of immune response is evaluated by comparing immunologic parameters before and after treatment; however, which of such parameters correlates with clinical response remains undetermined. 16 We and others have shown that the induction of antitumor CTL does not correlate with tumor regression in both humans [17] [18] [19] and mice. 15, 20 The present study corroborates this conclusion and shows that activation of CD8 cells is necessary but not sufficient to induce the eradication of lung metastases. In this tumor model antitumor CD8 T lymphocytes displayed a different pattern of reactivity between mice that were cured or not cured by vaccination, and efficiently caused tumor immunoselection. Successful therapy was clearly associated with activation of CD8 T cells endowed with GM-CSF production and with specificity for antigens that are not lost during tumor progression.
Although this model is artificial because of transgene expression under an heterogous promoter, our finding may offer a possible interpretation of events occurring following vaccination with cytokine-transduced tumor cells. It is likely that the outgrowth of antigen loss tumor variants is causally associated with the therapeutic efficacy of the treatment. If the target antigen of the dominant response is immunoselected, the weaker response to the remaining antigen(s) may not be sufficient to cause tumor eradication. In this view, tumor escapes if CTL are primed against antigens that can be lost. When the response directed against the C26-related TAAs was strong enough all mice were cured whereas a dominant response to the FR␣ antigen resulted in the outgrowth of antigen loss tumors. In fact, tumors from mice which died despite vaccination were negative for FR␣ but positive for C26-TAAs. The different specificity of the CTL response can be due to the early expansion of the few CTLp that first encounter a certain tumor antigen. In the P815 tumor model CTL response has been shown to be directed against different TAAs when individual responses were considered. 21 Of course, the expression of FR␣ cannot be examined in tumors from cured mice, thus antigen loss cannot be causally associated with the failure of immunotherapeutic treatment. Reduction of FR␣ positivity below 50% was observed when tumors were examined after vaccination, while FR␣ expression remained Ͼ50% in CD8-depleted mice. Since it cannot be excluded that both rejected and non-rejected tumors had lost expression of FR␣, tumor eradication may ultimately depend on the occurrence of 'epitope spreading' including other TAA following the response against FR␣. 22 In this view CD8-released GM-CSF may also be instrumental for the initiation of a response against subdominant epitopes, through APC recruitment, activation and processing of other antigens. The higher frequency of T cells producing GM-CSF may reflect the stronger CTL activation occurring in responders.
Heterogeneity of tumors may represent a substantial problem for immunotherapy. Different mechanisms of tumor escape from immune attack are likely to operate in vivo and tumor immunoselection has been documented in cancer patients after treatment and in preclinical studies also. [7] [8] [9] [23] [24] [25] Our data indicate that CD8 response can be efficient in selecting antigen loss tumor variants. The use of an artificial system hampered the difficulties of investigating the mechanism of immunoselection. However, transducing human FR␣ gene into C26 allowed the increase of the antigenic repertoire of the tumor such to include a strong, known antigen which may undergo immunoselection. Other tumor models which display more than two endogenous known or detectable antigens are not available. Furthermore, by placing the FR␣ gene under the LTR promoter we were able to document that immunoselection was associated with promoter downregulation since treatment with the demethylating agent aza partially restored FR␣ TAA expression by immunoselected tumors. This finding may be relevant since aza treatment has been shown to induce the expression of MAGE-1 in melanoma and melanocytes 26, 27 indicating that demethylation can affect the expression of TAA which are silent in normal tissues. We have also observed that aza treatment induced the expression of AH1 TAA in F1 transformed fibroblasts (M Rodolfo, unpublished). Further experiments are needed to see whether CD8 immunoselection may occur through methylation of TAA promoters other than retroviral LTR. Transcriptional inactivation of proviral LTR by methylation has been described in hematopoietic stem cells, in fibroblasts and in embryonic stem cells. 28 IL-12 production by cell vaccine was shown to be instrumental in obtaining a curative response in different tumor models; furthermore, its presence ensures that a Th1 type response is induced independently by the nature of the stimulating antigens.
14 In fact, lymphocytes from both responder and nonresponder mice were cytotoxic and able to produce IFN␥. Although local production of IFN␥ has been associated with a favorable outcome of therapy in different models, 29, 30 in the present study production of GM-CSF was the hallmark of lymphocytes from responder mice. The ability to produce GM-CSF has been associated with the therapeutic activity of CD8 lymphocytes in other preclinical studies, 31 and GM-CSF production by infused T cells appeared to be an important predictor of tumor response in melanoma and renal cancer patients. 32, 33 GM-CSF released by antigenspecific T cells which reach the tumor site may either potentiate the effect of concomitant produced IFN␥ and other secondary cytokines, and recruit and activate macrophages and granulocytes that are associated with tumor killing through nonspecific bystander effects. 6, 34, 35 In addition, we showed that GM-CSF can substitute for IFN␥ in inducing rejection of C26/IL-12 injected into IFN␥ KO mice. 36 IL-12 has also been reported to modulate immunodominance of cytotoxic T lymphocytes epitopes coinjected in vivo. 37 The detection of CTL specific for C26-related TAA other than the immunodominant AH1 in lymphocytes from responder mice suggests that IL-12 produced by tumor vaccines may modulate TAA immunodominance. AH1 peptide has been eluted from CT26 and described as immunodominant for CTL response but insufficient to stimulate antitumor response, probably because of the lack of a helper signal. 10 We may indirectly confirm its immunodominance, since 19 of 20 CTL clones obtained from C26 tumor-immune or tumor-bearing mice after repeated in vitro stimulations with irradiated C26 cells recognized the AH1 peptide. The remaining clone (9A/89), however, detects a different, as yet undefined TAA thus indicating the existence of additional antigens on C26 cells. Studies aimed at the identification of this TAA are in progress.
Materials and methods

FR␣ vector construction and retroviral transduction
A 910-bp EcoRI fragment of human gp38 FR␣ was cloned into the retroviral vector LXSN, that was oriented by restriction analysis and transfected into the amphotropic packaging cell line gp+AM12. Transiently produced virus particles were used to infect the ecotropic packaging gp+E86 as described.
15 C26 tumor cells, B10.HTG, B10.A(5R) (thereafter called HTG and 5R, respectively) and F1 BALB/c fibroblast cell lines were infected with the viral supernatant in the presence of polybrene and transduced cells were isolated by G418 selection. FR␣ expression was assayed by flow cytometry using the MOV19 mAb 38 and was shown to be stable over several months of continuous in vitro culture. 
Immunotherapy experiments
Two-month-old female BALB/cnAnCr mice obtained from Charles River (Calco, Italy) and maintained according to institutional and EC guidelines were used throughout the study. Immunotherapy experiments were carried out as described. 15 Lung metastases were induced by the i.v. injection of 5 × 10 3 C26/FR␣ cells and mice were vaccinated on days 3, 6, 9 and 13, by injecting s.c. 3 × 10 6 150 Gy irradiated tumor cells. CD4 and CD8 cell depletion were carried out by treating mice with mAbs GK1.5 or 2.43 (0.3 mg i.p.) on day 1 after i.v. tumor injection and every 2 weeks thereafter. For survival follow-up mice were killed when showing dyspnea. Vaccinated mice were tagged and individual lymphocyte samples were obtained on day 16 by hemisplenectomy under anesthesia.
Cell-mediated cytotoxicity assay and precursor (p) CTL determination in limiting dilution analysis (LDA) assay CTL response and specificity were assessed in standard 4 h 51 Cr-release assays after 6 days mixed lymphocyte tumor cell cultures (MLTC) as previously described. Cr-release assays were performed with 10 3 target cells/w. Values of lysis exceeding three times the standard deviation of the mean spontaneous release were used as a threshold for scoring positive cytolysis. Calculation of the frequencies from limiting dilution data was based on the single-hit Poisson model. 39 Frequencies given by the number of responder cells corresponding to 37% negative cultures, were then calculated from the slope of the regression line. The same method was used for calculation of frequencies of GM-CSF producing CTLp. Fig P software (Biosoft, Cambridge, UK) was used to calculate the confidence limits of the regression line.
Cytokine production assay CD8 cells were enriched to 75-85% from MLTC lymphocytes by complement lysis of CD4 + cells after incubation with anti-CD4 mAb (GK1.5). In vitro cytokine production by CD8 cells from MLTC and by CTL clones was induced by incubating lymphocytes (1-2 × 10 5 /w) with stimulating tumor cells (10 5 /w) in 96-well plates for 24 h. Supernatants were assayed for cytokine content by specific ELISA (PharMingen, San Diego, CA, USA).
Ex vivo tumor cell analysis
Lungs were removed from mice found dead during the survival follow-up or those killed after the course of vaccinations, and tumor cells were obtained by enzymatic digestion. Cells were kept in culture for at least three passages in order to eliminate contaminating normal cells. Treatment with 5-aza-2Ј-deoxycytidine (SigmaAldrich, Milan, Italy) was set on semiconfluent tumor cells (10 
